Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPC

Excerpt:

“Treatment with apalutamide (Erleada) was not associated with a significant impact on health-related quality of life (HRQoL) in patients with high-risk nonmetastatic castration-resistant prostate cancer, according to patient-reported outcome (PRO) data from the phase III SPARTAN trial.

“In the study overall, patients treated with the addition of apalutamide to standard hormone therapy also had an improvement in metastasis-free survival (MFS) and longer time to symptomatic progression compared with those who were treated with placebo.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Xtandi Granted Priority Review for Prostate Cancer Treatment

Excerpt:

“The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

“The sNDA is based on data from the phase 3 PROSPER trial in which the combination of Xtandi and androgen deprivation therapy (ADT) reduced the risk of metastases or death by 71 percent compared with ADT alone for patients with nonmetastatic CRPC. In the double-blind study, the median metastasis-free survival (MFS) was 36.6 months with Xtandi plus ADT versus 14.7 months with ADT alone.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Investigational Prostate Cancer Drug Decreased PSA Levels with Low Toxicity

The gist: Researchers conducted a clinical trial with volunteer patients to test a new drug for nonmetastatic castration-resistant prostate cancer. Patients participating in the trial were treated with the drug orteronel. It was found that orteronel decreased PSA levels (high PSA levels may correlate with worsening disease).

“Monotherapy with the investigational agent orteronel decreased PSA levels in patients with nonmetastatic castration-resistant prostate cancer, according to results of a phase 2 study.

“Toxicities were moderate and manageable, and administration of the drug without steroids appeared to be feasible, Maha Hussain, MD, FACP, professor of medicine and urology at the University of Michigan Comprehensive Cancer Center, and colleagues wrote.”